Celgene Post Doc, Predictive Modeling in Summit, New Jersey


Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, ​quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.


As a postdoctoral fellow in the Pharmaceutical Sciences and Technology Department based in Summit, NJ, you will collaborate closely with a highly motivated cross-functional team of engineers and pharmaceutical scientists to design and develop computational models for pharmaceutical unit operations. Through experimental design, material science and predictive modeling, you will develop new technologies and methodologies that are capable of producing drug substance and drug product with desired physical properties, in some cases, generating tailored attributes not accessibly through batch processing. This work will advance the field of continuous processing in the pharmaceutical industry as well as enhance the understanding of product development.

Responsibilities will include, but are not limited to, the following:

Designing, developing and performing batch and continuous predictive models and characterizing these processes through a variety of in-line and off-line predictive tools. Establishing an appropriate control strategy and optimizing processes to achieve product with desired attributes. Techniques are expected to include evaluation of product control via artificial intelligence and model-based predictive approaches. Developing robust process models to understand and characterize the variables that impact product attributes. Establishing an overarching strategy for design and scale up of robust unit operations. Multiple potential designs will be used to maximize the opportunity for tuning of product attributes using the predictive models.

Skills/Knowledge Required:

Working knowledge of key pharmaceutical unit operations both in drug substance and drug product including, but not limited to, crystallization, mixing, milling, granulation (wet and dry), tablet compression, and coating. Laboratory hands-on experience. Big data interpretation, manuscript preparation, publication and presentation of results.

Preferred Experience and Skills:

Ph.D. in in computational science & engineering, mechanical engineering and/or materials science & engineering with less than 3 years of postdoctoral experience preferred.

Proficient in 3D drawing & particulate modeling, process modeling, graphical user interface, and Matlab. Proficient in programming languages such as Python, C++, Fortran, and R. Familiarity with a variety of material characterization and PAT tools.


Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.